To evaluate the efficacy and safety of Jing Fang Wu Mei Wan Jiawei Fang in the treatment of idiopathic blepharospasm using a clinical randomized controlled trial method.
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
The degree of relief of blepharospasm was evaluated by Jankovic Rating Scale.
Timeframe: Six months
The Blepharospasm Disability Index (BSDI) was used to evaluate the impact of blepharospasm on daily living activities before and after treatment.
Timeframe: Six months
Traditional Chinese Medicine（TCM） syndrome scale evaluated the change of systemic syndrome before and after treatment.
Timeframe: Six months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Timeframe: Six months
According to the Jankovic rating scale, the recurrence was determined at 14 days, 42 days, 3 months and 6 months after medication
Timeframe: Six months
Number of participants with treatment-related adverse events as assessed by systemic response, routine blood tests, liver function (ALT), kidney function (BUN, Cr).
Timeframe: Six months